Innovent Biologics, Inc. Financials

Market Capitalization HK$160.86 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	101.67
Forward PE	38.40
Price to Sales TTM	HK$11.49
Price to Book MRQ	HK$7.86
Enterprise to Revenue	10.50
Enterprise to EBITDA	92.07

Financial Reports as of Jun. 30, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-06-30
Profit Margin	9.91%
Operating Margin	12.99%
Return on Assets TTM	2.65%
Return on Equity TTM	8.44%

Income Statement

Revenue TTM	HK$12,722,250,920
Revenue per Share TTM	HK$6.98
Quarterly Revenue Growth	50.60%
Gross Profit TTM	HK$9,747,458,427
EBITDA	HK$281,505,367
Net Income to Common TTM	HK$1,261,132,926
Diluted EPS TTM	HK$0.75
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	HK$10,625,520,622
Total Cash per Share MRQ	HK$5.77
Total Debt MRQ	HK$
Total Debt to Equity MRQ	23.43
Current Ratio MRQ	2.61
Book Value per Share MRQ	HK$9.70

Cash Flow

Operating Cash Flow TTM	HK$2,023,077,489
Levered Free Cash Flow TTM	HK$99,546,392

1801 Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	1,653,522,664
Float Shares	1,537,941,430
Avg 10 Volume	10,059,843
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	6.45%
% Held by Institutions	52.43%

Stock Price Summary

Beta	0.46
Fifty Two Week Low	HK$28.65
Fifty Two Week High	HK$109.10
Fifty Two Week Change	55.20%
Day 50 MA	HK$86.62
Day 200 MA	HK$79.01

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date